Wafik El-Deiry: Clinical development portfolio at AACR24 by Michael Pourdehnad
Wafik El-Deiry, Director of the Legorreta Cancer Center at Brown University, recently posted on LinkedIn:
“Listening to Michael Pourdehnad at Bristol Myers Squibb at the American Association for Cancer Research (AACR) 2024.
Directions at Bristol Myers Squibb in oncology at AACR24 with evolving portfolio of NME’s. He spoke about the broad therapeutic areas.
Causal human biology and unmet need gets matched to modality and a path to clinical proof-of-concept. AI-assisted molecule invention, investing in models and diagnostics. Models are critical. Modality toolbox.
Power of computation, AI/Digital tools, collaborations and differentiating platforms. Degrades and Cell Therapies. Targeted protein degradation vastly expands universe of targets for disease therapy.
Molecular glues, Protacs, ADCs with warhead degraders as well as pipeline. Massive proteomics with Evotech has lad to an expanding library of degraders and it keeps expanding not plateauing. Example to increase fetal hemoglobin in sickle cell.
In absence of a degron, ligand directed degraders. Example of AR degrader for prostate cancer, broad activity in patients. Cell Therapy at AACR24. Strategy to accelerate development. Clinical development portfolio at AACR24.”
Source: Wafik El-Deiry/LinkedIn
